We bring over 15 years of experience in biofilm R&D to market, developing next-generation antimicrobials against resistant biofilm-related infections.

We are at the front door of a global AMR silent pandemic. 
Where antibiotics fail, our solution begins.

How BIG is the problem?

Biofilms are the source of a significant medical unmet need:
Responsible for +80% human chronic infections.
Enables bacteria to be 1,000 times more resistant to antibiotics, causing treatment failure in 8 out of 10 cases.
Emerging innovative treatment alternatives have still limited effectiveness and stability.
400B is the global annual spent in human biofilm-related infections.

Resistia

Org chart

Teams

Offices